Research Summary

Analyzed using Evidence Intelligence™

Novel Semaglutide Injection Shows Non-Inferior Glycemic Control

Key finding

HbA1c decreased from 8.36 % to 6.81 % in the test group.

This Phase 3 trial evaluated a novel semaglutide injection in Indian adults with Type 2 diabetes, showing significant reductions in HbA1c and body weight.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias

Last updated July 4, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Once-weekly semaglutide injection

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

HbA1c at 24 weeks

Comparator

Reference semaglutide injection (comparator)

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This Phase 3 trial evaluated a novel semaglutide injection in Indian adults with Type 2 diabetes, showing significant reductions in HbA1c and body weight.

Clinical relevance

These findings are significant as they suggest that the novel semaglutide injection could be an effective treatment option for managing Type 2 diabetes in Indian adults. By improving blood sugar control and reducing body weight, this treatment may help lower the risk of diabetes-related complications, enhancing the quality of life for patients.

Keep in mind

The study's generalizability may be limited to the Indian population. Potential biases in self-reported outcomes were not addressed. The long-term effects of the treatment were not evaluated.

Published in

Journal Reference

Publication details and source links for this paper.

Prabhat KS, V. V, Animesh C, et al. A Phase 3 Trial of a Novel Semaglutide Injection in Indian Adults with Type 2 Diabetes. Metabolism Open. 2026;30:100476. doi:10.1016/j.metop.2026.100476

View DOI View on PubMed View on PMC

Save this study and add notes to your research library.

Main Effects

HbA1c decreased by 1.55% in the test group (p=0.001).

Fasting plasma glucose decreased by 37.5 mg/dL in the test group.

Body weight decreased by 4.59 kg in the test group.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide and Adverse events incidence, BMI, Body weight, and 6 more.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Adverse events incidence

Evidence topic

Adverse Events and Safety

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence
BMI
Body weight

Evidence topics

Adverse Events and Safety Glycemic Control Weight Loss HbA1c Reduction

Primary intervention

Semaglutide

Primary outcomes

Adverse events incidence BMI Body weight

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

Evidence pairs

Relationships

Evidence topics

contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

Why it is useful

Contributes to 9 evidence relationships
Includes primary outcome data
Linked to 5 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Semaglutide → Systolic blood pressure

Evidence profile

NoneDecreaseMetabolic Health

Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

Evidence Suggest

HbA1c levels decreased from 8.36% to 6.81% in the test group.
Body weight reduction of 4.59 kg was observed in the test group.
Hypoglycemia incidence was low at 1.9% in the test group.

Who this applies to

Indian adults aged 18 and older with Type 2 diabetes.
Individuals seeking effective management options for diabetes.

Keep in Mind

Results may not be applicable to populations outside India.
The study did not assess long-term safety and efficacy.
Variability in individual responses to treatment may occur.

Between the Lines

The study's generalizability may be limited to the Indian population.
Potential biases in self-reported outcomes were not addressed.
The long-term effects of the treatment were not evaluated.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

GLP-1 Receptor AgonistsHbA1c

Medications

11 studies

Detailed evidence

GLP-1 Receptor AgonistsBody Weight

Medications

10 studies

Detailed evidence

GLP-1 Receptor AgonistsBlood Pressure

Medications

2 studies

Detailed evidence

Included in these evidence collections

Curated evidence collections and hubs this study is part of.

GLP-1 Receptor Agonists Evidence Hub

All studies on GLP-1 Receptor Agonists

11 studies

intervention_hub

Contributes to GLP-1 Receptor Agonists evidence base.

HbA1c Evidence Hub

All studies measuring HbA1c

11 studies

outcome_hub

Measures HbA1c as a key outcome.

Body Weight Evidence Hub

All studies measuring Body Weight

10 studies

outcome_hub

Measures Body Weight as a key outcome.

Blood Pressure Evidence Hub

All studies measuring Blood Pressure

2 studies

outcome_hub

Measures Blood Pressure as a key outcome.

Recent Diabetes Research

Latest published studies

recency_collection

Published within the last 2 years.

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists improve HbA1c?

Moderate Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.8 | strong positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body weight?

Emerging Evidence

GLP-1 Receptor Agonists may improve Body Weight.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Moderate | EvidenceScore™ 66.2 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists affect body mass index?

Emerging Evidence

GLP-1 Receptor Agonists may improve Body Mass Index.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

1
BMI
EvidenceScore™ Emerging | EvidenceScore™ 55.2 | moderate positive | ConsensusScore™ Consistent | 1 study

Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

View Full Evidence

Does GLP-1 Receptor Agonists improve blood pressure?

Emerging Evidence

Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Blood Pressure.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Diastolic blood pressure
EvidenceScore™ Limited | EvidenceScore™ 37.1 | neutral | ConsensusScore™ Mixed | 1 study
2
Systolic blood pressure
EvidenceScore™ Limited | EvidenceScore™ 37.1 | neutral | ConsensusScore™ Mixed | 1 study

Why this answer: This answer is based on 7 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

View Full Evidence

Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Adverse Events and Safety Evidence Hub Glycemic Control Evidence Hub Weight Loss Evidence Hub HbA1c Reduction Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Semaglutide and HbA1c All studies on Semaglutide and Body weight All studies on Semaglutide and BMI All studies on Semaglutide and Adverse events incidence

Related research

Read related research summaries.

Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetes Higher semaglutide doses improve glucose control in type 2 diabetes Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.